Onconetix, Inc. (NASDAQ:ONCO) Short Interest Up 98.4% in July

Posted by Stephan Jacobs on Jul 29th, 2026

Onconetix, Inc. (NASDAQ:ONCO – Get Free Report) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 122,244 shares, an increase of 98.4% from the June 30th total of 61,615 shares. Based on an average daily volume of 1,025,036 shares, the days-to-cover ratio is currently 0.1 days. Approximately 10.8% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several research analysts have commented on ONCO shares. Weiss Ratings raised Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, July 15th. Wall Street Zen downgraded Onconetix from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Onconetix currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on Onconetix

Onconetix Stock Down 9.7%

ONCO traded down $0.08 during trading on Wednesday, reaching $0.75. 1,121,313 shares of the stock traded hands, compared to its average volume of 718,646. The stock’s 50-day moving average is $1.00 and its 200 day moving average is $22.97. Onconetix has a 12 month low of $0.71 and a 12 month high of $229.50. The stock has a market capitalization of $854,202.00, a PE ratio of 0.07 and a beta of 2.69.

Hedge Funds Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Citadel Advisors LLC purchased a new position in shares of Onconetix, Inc. (NASDAQ:ONCO – Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 1.00% of Onconetix as of its most recent filing with the SEC. Institutional investors own 23.89% of the company’s stock.

About Onconetix

(Get Free Report)

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.